![Placeholder Image Placeholder Image](https://prod1.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
-
Media ReleaseNovartis Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
-
Media ReleaseDie Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrats gut
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelle
-
Media ReleaseNovartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
-
Media ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
-
Media ReleaseNovartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
-
Media ReleaseNovartis announces change to the Executive Committee
-
Media ReleaseNovartis appoints Karen Hale as Chief Legal Officer
-
Media ReleaseNew Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
-
Media ReleaseNovartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
-
Media ReleaseNovartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Pagination
- ‹ Previous page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- …
- 32
- › Next page